cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Vor Biopharma Inc
1 own
1 watching
Current Price
$0
$0.14
(2.65%)
logo-vor
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
203.1M
52-Week High
52-Week High
9.72
52-Week Low
52-Week Low
3.48
Average Volume
Average Volume
0.02M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization203.1M
icon52-Week High9.72
icon52-Week Low3.48
iconAverage Volume0.02M
iconDividend Yield--
iconP/E Ratio--
What does the Vor Biopharma Inc do?
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Vor Biopharma Inc make?
News & Events about Vor Biopharma Inc.
Globe Newswire
14days ago
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly VOR33) in ...
Globe Newswire
21days ago
CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities 3rd Annual Oncology Conference. B. Riley Securities 3rd Annual Oncology Conference Fireside...
Benzinga
23days ago
Vor Biopharma's (NASDAQ:VOR) short percent of float has fallen 58.58% since its last report. The company recently reported that it has 2.53 million shares sold short, which is 5.31% of all regular shares that are available for trading. read more...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Piper Sandler 34th Annual Healthcare ConferencePresentation: Tuesday, November 29...
Globe Newswire
7 months ago
Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for treatment of acute myeloid leukemia Dual edited hematopoietic stem and progenitor cells persisted long-term post engraftment, with minimum ...
Frequently Asked Questions
Frequently Asked Questions
What is Vor Biopharma Inc share price today?
plus_minus_icon
Can Indians buy Vor Biopharma Inc shares?
plus_minus_icon
How can I buy Vor Biopharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Vor Biopharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Vor Biopharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Vor Biopharma Inc?
plus_minus_icon
What is today’s market capitalisation of Vor Biopharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Vor Biopharma Inc?
plus_minus_icon
What percentage is Vor Biopharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Vor Biopharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.14
(2.65%)
logo-vor
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00